Posttraumatic Stress Disorder: An Integrated Overview of the Neurobiological Rationale for Pharmacology. Issue 3 (18th July 2017)

• Record Type: Journal Article
• Authors: Kelmendi, Benjamin; Adams, Thomas G.; Southwick, Steven; Abdallah, Chadi G.; Krystal, John H.
• Is Part Of: Clinical psychology. Volume 24:Issue 3(2017)
• Page Start: 281
• Page End: 297
• Publication Date: 2017-07-18
• Subjects: gamma‐amino‐butyric acid -- glutamate -- noradrenergic -- pharmacology -- posttraumatic stress disorder -- serotonin; Clinical psychology -- Periodicals; Psychology, Pathological -- Periodicals; Psychotherapy -- Periodicals; 616.89
• DOI: 10.1111/cpsp.12202
• Languages: English
• ISSNs: 0969-5893

Abstract

Abstract : Thirty years of research on the biology of posttraumatic stress disorder now provides a foundation for hypotheses related to the mechanisms underlying the pharmacotherapy of this disorder. Only two medications, sertraline and paroxetine, are approved by the U.S. Food and Drug Administration for the treatment of PTSD. Although these medications are somewhat effective, other treatment mechanisms must be explored to address the unmet need for effective treatment. This article provides a concise summary of advances in our understanding of the neurobiology of PTSD and novel approaches to pharmacotherapy.